This company is no longer active
HGEN.Q Stock Overview
A clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Humanigen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.21 |
| 52 Week Low | US$0.000001 |
| Beta | -1.34 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -100.00% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M
Aug 12Humanigen plunges 57% as trial for COVID-19 therapy fails
Jul 13Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy
Jul 06Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?
Oct 30
Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?
Jul 14Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.
Jun 14Humanigen submits lenzilumab COVID-19 EUA application to FDA
May 28Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy
May 05Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price
May 05We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon
Mar 31Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?
Feb 26Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19
Jan 29Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment
Jan 11We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth
Jan 04
Humanigen secures new U.S. patent for lenzilumab
Dec 28Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme
Dec 17Humanigen EPS misses by $0.16
Nov 11Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19
Nov 06Humanigen executes lenzilumab licensing deal in Asia for COVID-19
Nov 03Humanigen Dosing Phase 3 Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma
Nov 01Dosing underway in lenzilumab late-stage study in COVID-19
Oct 30Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19
Oct 29Shareholder Returns
| HGEN.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -99.5% | 2.4% | 2.2% |
| 1Y | -100.0% | 16.2% | 31.7% |
Return vs Industry: HGEN.Q underperformed the US Biotechs industry which returned 14% over the past year.
Return vs Market: HGEN.Q underperformed the US Market which returned 22% over the past year.
Price Volatility
| HGEN.Q volatility | |
|---|---|
| HGEN.Q Average Weekly Movement | 102,515.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HGEN.Q's share price has been volatile over the past 3 months.
Volatility Over Time: HGEN.Q's weekly volatility has increased from 50618% to 102515% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 6 | Cameron Durrant | www.humanigen.com |
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis.
Humanigen, Inc. Fundamentals Summary
| HGEN.Q fundamental statistics | |
|---|---|
| Market cap | US$119.00 |
| Earnings (TTM) | -US$53.63m |
| Revenue (TTM) | US$1.70m |
0.0x
P/S Ratio0.0x
P/E RatioIs HGEN.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HGEN.Q income statement (TTM) | |
|---|---|
| Revenue | US$1.70m |
| Cost of Revenue | US$38.73m |
| Gross Profit | -US$37.03m |
| Other Expenses | US$16.61m |
| Earnings | -US$53.63m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.45 |
| Gross Margin | -2,179.40% |
| Net Profit Margin | -3,156.80% |
| Debt/Equity Ratio | 0% |
How did HGEN.Q perform over the long term?
See historical performance and comparison